Close mobile menu×
Close mobile menu

David J. Lederer, MD

Board Certifications: 
Pulmonary Disease Medicine, Internal Medicine, Critical Care Medicine
Accepting New Patients
Profile Headshot

Appointments

Phone Appointments

New and Existing Patients: 
(212) 305-8203

myColumbiaDoctors

For existing patients, login to make an appointment, view documentation or contact your care provider.

Credentials & Experience

America's Top Doctor
NY Top Doctor

Board Certifications

  • Pulmonary Disease Medicine
  • Internal Medicine
  • Critical Care Medicine

Clinical Expertise

  • Pulmonary Fibrosis
  • Interstitial Pulmonary Fibrosis
  • Chronic Lung Disease
  • Interstitial Lung Disease
  • Idiopathic Pulmonary Fibrosis

Education & Training

  • State University of New York - Downstate Health Sciences Center
  • Residency: NewYork-Presbyterian Hospital/Columbia University Medical Center
  • Fellowship: NewYork-Presbyterian Hospital/Columbia University Medical Center

About David Lederer

David J. Lederer, MD, MS is the Co-Director of the New York Presbyterian/Columbia University Interstitial Lung Disease Program and Pulmonary Director of the Pulmonary & Intensive Care Translational Outcomes (PICTOR) Group at Columbia University. He is the principal investigator of two NHLBI-funded studies: the MESA Lung Fibrosis Study and the Lung Transplant Body Composition Study. He is the editor-in-chief of the Annals of the American Thoracic Society and sits on the editorial board of the American Journal of Respiratory and Critical Care Medicine. Dr. Lederer is a Senior Medical Advisor for the Pulmonary Fibrosis Foundation and a standing member of the IRAP study section at the Center for Scientific Review at the NIH and the NHLBI K23 study section. 

Academic Titles

  • Associate Professor of Medicine and Epidemiology (in Pediatrics)

Administrative Positions

  • Co-Director, Interstitial Lung Disease Program
  • Pulmonary Director, Pulmonary & Intensive Care Translational Outcomes Research (PICTOR) Group
  • Senior Medical Advisor, Pulmonary Fibrosis Foundation

Hospital Affiliations

  • NewYork-Presbyterian/Columbia

Gender

  • Male

Insurance Accepted

Aetna

  • EPO
  • HMO
  • Medicare Managed Care
  • NY Signature
  • POS
  • PPO
  • Signature Administrators
  • Student Health

Affinity

  • Essential Plan
  • Medicaid Managed Care
  • Medicare Managed Care

Amida Care

  • Special Needs Plan

Cigna

  • EPO
  • Great West
  • HMO
  • POS
  • PPO

Emblem/GHI

  • HMO
  • Medicare Managed Care
  • PPO

Emblem/HIP

  • ConnectiCare
  • EPO
  • Essential Plan
  • HMO
  • Medicaid Managed Care
  • Medicare Managed Care
  • POS
  • PPO
  • Select Care (Exchange)
  • Vytra

Empire Blue Cross Blue Shield

  • Blue Priority
  • EPO
  • HMO
  • Medicare (Mediblue)
  • NYP Employee Plan
  • Pathway (Exchange)
  • POS
  • PPO

Empire Blue Cross Blue Shield HealthPlus

  • Child/Family Health Plus
  • Essential Plan
  • Medicaid Managed Care

Fidelis Care

  • Child/Family Health Plus
  • Medicaid Managed Care
  • Medicare Managed Care

Healthfirst

  • Child/Family Health Plus
  • Medicaid Managed Care
  • Medicare Managed Care

Local 1199

  • Local 1199

MagnaCare

  • MagnaCare

Multiplan

  • Multiplan

Oxford Health Plans

  • Freedom
  • Liberty
  • Medicare Managed Care

POMCO

  • POMCO

UnitedHealthcare

  • Columbia University Employee Plan
  • Compass (Exchange)
  • EPO
  • Essential Plan
  • HMO
  • Medicaid (Community Plan)
  • Medicare Managed Care
  • POS
  • PPO

VNSNY CHOICE

  • Medicare Managed Care
  • SelectHealth

WellCare

  • Medicaid Managed Care
  • Medicare Managed Care

*Please contact the provider’s office directly to verify that your particular insurance is accepted.

Contact & Locations

1
161 Fort Washington Avenue
Room 321A
New York, New York 10032
Phone:
(212) 305-8203
Fax:
(212) 305-8426
Primary

Research

Dr. Lederer is the principal investigator of the MESA ILD Study and the Columbia IPF Study, studies funded by the National Heart, Lung, and Blood Institute and the Robert Wood Johnson Foundation. His research focuses on the causes of human lung fibrosis (including idiopathic pulmonary fibrosis, subclinical interstitial lung disease, and lung transplant-associated bronchiolitis obliterans) and outcomes after lung transplantation.

Research Interests

  • Disparities in access to subspecialty pulmonary services and lung transplantation
  • Body composition and lung transplantation
  • Subclinical interstitial lung disease
  • Obstructive sleep apnea and alveolar injury

Grants

R01 HL103676 (Lederer) 04/15/2011 – 04/14/2015
NIH/NHLBI 
Subclinical Interstitial Lung Disease in MESA 
The Aims of this project are to validate high attenuation areas (HAA) on CT lung imaging as a marker of subclinical interstitial lung disease and perform genome wide association and linkage studies of HAA. 
Role: PI
 
R01 HL081619 (Christie) 02/15/2007 – 01/31/2013 
NIH/NHLBI 
Genetics of Primary Graft Dysfunction
This study aims to identify genetic predictors of predict primary graft failure after lung transplant.
Role: Co-Investigator (Columbia site PI)
 
R01 HL087115 (Christie) 08/15/2007 – 07/31/2012 
NIH/NHLBI 
Clinical Risk Factors for Primary Graft Dysfunction
This is a study to identify clinical predictors of primary graft failure after lung transplantation.
Role: Co-Investigator (Columbia site PI)
 
R25 HL105401 (Begg) 09/25/2010 – 07/31/2014
FIRST in CER (Facilitating Independence in Research through the Summer Training in Comparative Effectiveness Research) Diversity Program
This program provides summer training and mentoring in skills essential to conducting comparative effectiveness research (CER), enhancing the career development of faculty and scientists from diverse backgrounds in basic and applied sciences relevant to heart, lung, blood, and sleep disorders.
Role: Collaborator
 
R25 HL096260 (Begg) 05/15/2009 – 04/30/2014
BEST-DP: Biostatistics Enrichment Summer Training Diversity Program 
This program provides research opportunities in biostatistics, cardiovascular disease, and pulmonary disease for individuals who are under- represented in biomedical research (those from disadvantaged backgrounds, racial and ethnic minorities, and individuals with disabilities), and who will contribute to a more diverse research workforce in the future.
Role: Collaborator
 
BI 1199.32 07/01/2011– 12/31/2015
Boehringer-Ingleheim 
A 52 week, double-blind, randomized, placebo-controlled trial evaluating the effect of oral BIBF 1120, 150mg twice daily, on annual FVC decline in patients with IPF
This is a multicenter clinical trial of BIBF 1120 to treat IPF.
Role: Columbia site PI
 
Irving Pilot Award 07/01/2012– 06/30/2013
Irving Institute for Clinical and Translational Research (Columbia CTSA) 
Obesity, Lung Transplantation, and Lung Injury
The major goal of this pilot study is to examine the use of quantitative CT imaging to ascertain adipose tissue distribution in lung transplant candidates.
Role: PI
 
U01 HL105371 (Choi) 03/01/2012– 06/30/2014
NIH/NHLBI 
Phase II Study of Inhaled Carbon Monoxide for the Treatment of IPF 
The purpose of this study is test the safety and efficacy of inhaled carbon monoxide in IPF.
Role: Co-investigator (Columbia site PI)
 
R01 HL114468 (Hancock) 05/15/2012 – 03/31/2016 
NIH/NHLBI 
Foxp3+ Treg Cells & Primary Graft Dysfunction in Clinical Lung Tx Recipients 
The Aims of this project are to examine role of Treg cells in primary graft dysfunction after lung transplantation.
Role: Co-investigator (Columbia site PI)

MODELING, PATHOGENESIS AND TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS (Federal Gov)

Sep 20 2016 - May 31 2023

FRAILTY IN LUNG TRANSPLANTATION. PLEASE NOTE THAT THE TITLE IS A WORKING TITLE SO THE PI S MAY UPDATE (Federal Gov)

Jul 1 2017 - Jun 30 2022

OBSTRUCTIVE SLEEP APNEA AND SUBCLINICAL LUNG INJURY IN HEALTH AND DISEASE (Federal Gov)

Jan 15 2018 - Dec 31 2021

MENTORED PATIENT ORIENTED RESEARCH IN PULMONARY FIBROSIS AND LUNG TRANSPLANTATION (Federal Gov)

Sep 1 2016 - Jul 31 2021

SUBCLINICAL INTERSTITIAL LUNG DISEASE IN MESA AND FAR-ILD (Federal Gov)

May 1 2017 - Apr 30 2021

GENOMIC AND TRANSCRIPTOMIC ANALYSIS OF EMPHYSEMA AND SUBCLINICAL LLD (Federal Gov)

May 15 2016 - Apr 30 2021

OBSERVATION REGISTRY FOR INTERSTITIAL LUNG DISEASES: PFF PATIENT REGISTRY (Private)

Apr 18 2016 - Oct 31 2020

IDIOPATHIC PULMONARY FIBROSIS PROSPECTIVE OUTCOMES (IPF- PRO) REGISTRY (P&S Industry Clinical Trial)

Apr 2 2015 - Apr 2 2020

TRANSPLANT OPTIMIZATION USING FUNCTIONAL IMAGING (P&S Industry Clinical Trial)

Mar 18 2015 - Mar 18 2020

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE II STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RIOCIGUAT (0.5 MG, 1.0 MG, 1.5 MG, 2.0 MG AND 2.5 MG TID) IN PATIENTS WITH SYMPTOMATIC PULMONARY HYPERTENSION ASSOCIATED WITH IDIOPATHIC (P&S Industry Clinical Trial)

Nov 10 2014 - Nov 10 2019

RLDC: MOLECULAR PATHWAY-DRIVEN DIAGNOSTICS & THERAPEUTICS FOR RARE LUNG DISEASES (Federal Gov)

Sep 18 2014 - Jul 31 2019

A.PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF GS-6624 IN SUBJECTS WITH IDIOPATHIC PULMONARY FIBROSIS (RAINIER) (P&S Industry Clinical Trial)

Apr 26 2013 - Apr 26 2018

OBESITY, INFLAMMATION AND LUNG INJURY AFTER LUNG TRANSPLANTATION (Federal Gov)

May 23 2013 - Mar 31 2018

AN OPEN-LABEL EXTENSION TRIAL FOR THE LONG TERM SAFETY OF ORAL BIBF 1120 IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF) (P&S Industry Clinical Trial)

Feb 4 2013 - Feb 4 2018

AN OPEN-LABEL EXTENSION TRIAL OF THE LONG TERM SAFETY OF ORAL BIBF 1120 IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF) (P&S Industry Clinical Trial)

Feb 4 2013 - Feb 4 2018

A PHASE 2, RANDOMIZED DOSE-RANGING STUDY TO EVALUATE THE EFFICACY OF TRALOKINUMAB IN ADULTS WITH IDIOPATHIC PULMONARY FIBROSIS - CAT-354-1066 - AAAK5259 (P&S Industry Clinical Trial)

Jan 30 2013 - Jan 30 2018

A PHASE 2, RANDOMIZED DOSE-RANGING STUDY TO EVALUATE THE EFFICACY OF TRALOKINUMAB IN ADULTS WITH IDIOPATHIC PULMONARY FIBROSIS (P&S Industry Clinical Trial)

Jan 30 2013 - Jan 30 2018

CLINICAL RISK FACTORS FOR PRIMARY GRAFT DYSFUNCTION (Federal Gov)

Aug 1 2014 - Jun 30 2017

BIBF1120 (P&S Industry Clinical Trial)

Oct 10 2011 - Oct 10 2016

RLDC MOLECULAR PATHWAY-DRIVEN DIAGNOSTIC AND THERAPEUTICS FOR RARE LUNG DISEASES (Federal Gov)

Sep 18 2014 - Jul 31 2016

FOXP3+ TREG CELLS AND PRIMARY GRAFT DYSFUNCTION IN CLINICAL LUNG TRANSPLANT RECIPIENTS (Federal Gov)

May 15 2012 - Apr 30 2016

ARTEMIS PH: A PHASE3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PARALLEL-GROUP STUDY TO EVALUATE (P&S Industry Clinical Trial)

Dec 23 2009 - Dec 23 2014

PHASE II STUDY OF INHALES CARBON MONOXIDE FOR THE TREATMENT OF IPF (Federal Gov)

Mar 1 2012 - Jun 30 2014

ARTEMIS (P&S Industry Clinical Trial)

Jan 29 2009 - Jul 30 2013

SUBCLINICAL INTERSTITIAL LUNG DISEASE IN MESA: THE MESA LUNG FIBROSIS STUDY (Private)

May 1 2012 - Apr 30 2013

EXPLAINING RACIAL AND ETHNIC DISPARITIES IN IDIOPATHIC PULMONARY FIBROSIS (Federal Gov)

Apr 1 2008 - Mar 31 2013

GENCTICS OF PRIMARY GRAFT DYSFUNCTION (Federal Gov)

Feb 15 2007 - Jan 31 2013

CLINICAL RISK FACTORS FOR PRIMARY GRAFT DYSFUNCTION (Federal Gov)

Aug 15 2007 - Jul 31 2012

EXPLAINING RACIAL AND ETHNIC DISPARITIES IN IDIOPATHIC PULMO NARY FIBROSIS (Private)

Jul 1 2008 - Jun 30 2011

Selected Publications

  • Baldwin, MR, Arcasoy SM, Shah A, Sze J, Sonett JR, Lederer DJ. Hypoalbuminemia and early mortality after lung transplantation: a cohort study. Am J Transplant 2012;12(5):1256-67.
  • Hook JL, Arcasoy SM, Zemmel D, Bartels M, Kawut SM, Lederer DJ. Titrated oxygen requirement and prognostication in idiopathic pulmonary fibrosis. Eur Respir J 2012;39(2):359-65.
  • Lederer DJ, Kawut S, Wikersham N, Winterbottom C, Bhorade S, Palmer S, Lee J, Diamond J, Wille K, Weinacker A, Lama V, Crespo M, Orens J, Sonett J, Arcasoy S, Ware L, Christie J. Obesity and primary graft dysfunction after lung transplantation: the LTOG Obesity Study. Am J Respir Crit Care Med 2011;184:1055-61.
  • Lamas DJ, Kawut SM, Bagiella E, Philip N, Arcasoy SM, Lederer DJ. Delayed access and survival in idiopathic pulmonary fibrosis: a cohort study. Am J Respir Crit Care Med 2011;184:842-7.
  • Lederer DJ, Wilt JS, D’Ovidio F, Bacchetta M, Shah L, Ravichandran S, Lenoir J, Klein B, Sonett JR, Arcasoy SM. Obesity and underweight are associated with an increased risk of death after lung transplantation. Am J Respir Crit Care Med 2009;180(9):887-95.
  • Lederer DJ, Enright PL, Kawut SM, Hoffman EA, Hunninghake G, van Beek EJR, Austin JHM, Jiang R, Lovasi GS, Barr RG. Cigarette smoking is associated with subclinical parenchymal lung disease: The MESA-Lung Study. Am J Respir Crit Care Med 2009;180(5):407-14.
  • Lederer DJ¸ Jelic S, Basner RC, Ishizaka A, Bhattacharya J. Circulating KL-6, a biomarker of lung injury, in obstructive sleep apnea. Eur Respir J 2009;33(4):793-6.
  • Lederer DJ, Benn EKT, Barr RG, Wilt JS, Reilly G, Sonett JR, Arcasoy SM, Kawut SM. Racial differences in waiting list outcomes in COPD. Am J Respir Crit Care Med 2008;177(4):450-454.
  • Lederer DJ, Arcasoy SM, Barr RG, Wilt JS, Bagiella E, D'Ovidio F, Sonett JR, Kawut SM. Racial and ethnic disparities in idiopathic pulmonary fibrosis: A UNOS/OPTN database analysis. Am J Transplant 2006;6(10):2436-42.
  • Lederer DJ, Caplan-Shaw CE, O’Shea MK, Wilt JS, Basner RG, Bartels MN, Sonett JR, Arcasoy SM, Kawut SM. Racial and ethnic disparities in survival in lung transplant candidates with idiopathic pulmonary fibrosis. Am J Transplant 2006;6:398-403.